SITEMAP 창 닫기

CEO & President Wonbum Lee
Sales Revenue(2019) 159,177 Million KRW
Stock Exchange Index KOSPI
Head Office Seoul, Korea
KGMP Plant Anseong, Korea
R&D center Suwon, Korea / Seoul, Korea
Main Therapeutic Areas Central Nervous System (82%)
Cardiovascular (6%)
Gastrointestinal (4%)
Main Products Risperidone/Quetiapine/Alprazolam